WallStreetZenWallStreetZen

NASDAQ: ALNY
Alnylam Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ALNY past revenue growth

How has ALNY's revenue growth performed historically?
Company
28.24%
Industry
123.51%
Market
163.96%
ALNY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ALNY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ALNY's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ALNY earnings and revenue history

Current Revenue
$960.9M
Current Earnings
-$1.2B
Current Profit Margin
-123%

ALNY Return on Equity

Current Company
-430.7%
Current Industry
-9.8%
Current Market
-8.3%
ALNY's Return on Equity (-430.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ALNY announces earnings.

ALNY Return on Assets

Current Company
-33.9%
Current Industry
0.6%
ALNY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ALNY Return on Capital Employed

Current Company
-36.83%
Current Industry
11.2%
ALNY has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ALNY vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ALNY$960.92M-$935.29M-$1.18B+69.13%N/A
BGNE$1.25B-$2.09B-$2.15B+41.51%N/A
SGEN$1.86B-$552.70M-$636.77M+32.41%N/A
GMAB$1.59B$1.07B$747.88M+123.86%+128.11%
RPRX$2.25B$694.80M$506.82M+5.80%-41.24%
View Top Biotech Stocks

ALNY earnings dates

Next earnings date
Feb 23, 2023

Alnylam Pharmaceuticals Earnings & Revenue FAQ

What were ALNY's earnings last quarter?

On Invalid Date, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q3 2022 earnings per share (EPS) of -$3.32, up 93.02% year over year. Total Alnylam Pharmaceuticals earnings for the quarter were -$405.92 million. In the same quarter last year, Alnylam Pharmaceuticals's earnings per share (EPS) was -$1.72.

If you're new to stock investing, here's how to buy Alnylam Pharmaceuticals stock.

What was ALNY's earnings growth in the past year?

As of Q1 2023, Alnylam Pharmaceuticals's earnings has grown year over year. Alnylam Pharmaceuticals's earnings in the past year totalled -$1.18 billion.

What is ALNY's earnings date?

Alnylam Pharmaceuticals's earnings date is Invalid Date. Add ALNY to your watchlist to be reminded of ALNY's next earnings announcement.

What was ALNY's revenue last quarter?

On Invalid Date, Alnylam Pharmaceuticals (NASDAQ: ALNY) reported Q3 2022 revenue of $264.31 million up 40.86% year over year. In the same quarter last year, Alnylam Pharmaceuticals's revenue was $187.63 million.

What was ALNY's revenue growth in the past year?

As of Q1 2023, Alnylam Pharmaceuticals's revenue has grown 28.24% year over year. This is 95.27 percentage points lower than the US Biotechnology industry revenue growth rate of 123.51%. Alnylam Pharmaceuticals's revenue in the past year totalled $960.92 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.